Sonoma Biotherapeutics announced early clinical data today in a late-breaker at #ACR25 for its CAR-Treg to treat rheumatoid arthritis. Co-Founders Jeff Bluestone and Fred Ramsdell walk us through it.

They explain why they believe a Treg based cell therapy is the right approach for autoimmune conditions, and describe the construct of this particular product. After discussing the data, they also comment on what they believe the big picture is for these types of Treg based treatments going forward.